- 12-Week # shares bought: 70,000
- 24-Week # shares bought: 5.9 million
Regeneron has faced a lower stock price and patent wrangling. But the stock could be ready to rise again.
Look at what they are buying.
Jim Cramer says he's focusing on health-care companies that will break news that moves stocks.